Impact of Updating Pharmacogenetic Results: Lessons Learned from the PREDICT Program
Pharmacogenomic (PGx) evidence for selective serotonin reuptake inhibitors (SSRIs) continues to evolve. For sites offering testing, maintaining up-to-date interpretations and implementing new clinical decision support (CDS) driven by existing results creates practical and technical challenges. Vande...
Enregistré dans:
Auteurs principaux: | Michelle Liu, Sara L. Van Driest, Cindy L. Vnencak-Jones, Leigh Ann G. Saucier, Bartholomew P. Roland, Cheryl L. Gatto, Shari L. Just, Asli O. Weitkamp, Josh F. Peterson |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/59b4c678d0c74fe7be7ea8ccb90969b1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical applications of pharmacogenomics
par: Quiñones,Luis, et autres
Publié: (2017) -
Pharmacogenetics
Publié: (1991) -
Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies
par: L. K. Khokhlov, et autres
Publié: (2019) -
The pharmacogenomics journal
Publié: (2001) -
Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
par: Xandra García-González, et autres
Publié: (2021)